Uveitis - Pipeline Insight, 2025

This “Uveitis - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Uveitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Uveitis: Understanding

Uveitis: Overview

Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, which includes the iris, ciliary body, and choroid. This condition can lead to swelling, redness, pain, blurred vision, and light sensitivity. The inflammation can be classified based on its location within the eye: anterior uveitis affects the front part of the eye and is the most common form; intermediate uveitis affects the vitreous and peripheral retina; posterior uveitis involves the choroid and retina; and panuveitis affects all layers of the uvea. Uveitis can be acute, with a sudden onset and short duration, or chronic, persisting for months or even years.

The causes of uveitis are diverse, ranging from autoimmune disorders, infections, and trauma, to idiopathic origins where no specific cause is identified. Autoimmune conditions like rheumatoid arthritis, sarcoidosis, and ankylosing spondylitis are commonly associated with uveitis. Infectious agents, such as bacteria (e.g., tuberculosis, syphilis), viruses (e.g., herpes simplex, cytomegalovirus), fungi, and parasites, can also trigger inflammation. In many cases, the exact cause remains unknown, complicating diagnosis and treatment. A comprehensive medical evaluation, including blood tests, imaging, and possibly a biopsy, may be necessary to identify the underlying cause.

Treatment for uveitis aims to reduce inflammation, alleviate symptoms, and prevent complications such as glaucoma, cataracts, and vision loss. Corticosteroids, administered as eye drops, oral medications, or injections, are the mainstay of treatment. Immunosuppressive drugs may be used for severe or chronic cases, especially when autoimmune disorders are involved. Additionally, treating the underlying cause, whether it is an infection or systemic disease, is crucial for effective management. Regular follow-up with an ophthalmologist is essential to monitor the condition and adjust treatment as needed, ensuring the best possible outcomes for patients.

'Uveitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uveitis pipeline landscape is provided which includes the disease overview and Uveitis treatment guidelines. The assessment part of the report embraces, in depth Uveitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uveitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve Uveitis.

Uveitis Emerging Drugs Chapters

This segment of the Uveitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uveitis Emerging Drugs

Barcitinib: Eli Lilly and Company

Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor with less activity against the JAK family members, tyrosine kinase 2 and JAK3. Baricitinib modulates cytokine signaling pathways implicated in disease pathogenesis by partially inhibiting JAK1 and JAK2 enzymatic activity, resulting in reduced phosphorylation and activation of signal transducers and activators of transcription (STATs) and reduced inflammation, cellular activation, and proliferation of key immune cells. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Uveitis.

VVN461: VivaVision Biotech, Inc

VVN461 is an ophthalmic Solution developed by VivaVision Biotech, designed to treat patients with noninfectious anterior uveitis. It is characterized as a non-steroidal dual JAK1/TYK2 immunomodulator, which works by inhibiting multiple inflammatory cytokine pathways to reduce inflammation effectively. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Uveitis.

RAY 121: Chugai Pharmaceutical

RAY-121 is a therapeutic antibody developed by Chugai Pharmaceutical, utilizing their proprietary Recycling Antibody technology. This innovative approach allows RAY-121 to selectively bind to complement C1s, thereby inhibiting the classical complement pathway (CP). This mechanism is expected to provide enhanced efficacy and safety compared to traditional C3/C5 inhibitors in treating various autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Uveitis.

Uveitis: Therapeutic Assessment

This segment of the report provides insights about the different Uveitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Uveitis

• There are approx. 15+ key companies which are developing the therapies for Uveitis. The companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

Phases

The report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uveitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uveitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uveitis drugs.

Uveitis Report Insights

• Uveitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uveitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uveitis drugs?
• How many Uveitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uveitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uveitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uveitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• VivaVision Biotech, Inc
• Eyevensys
• SFA Therapeutics
• Tarsier Pharma
• Chugai Pharmaceutical

Key Products

• Baricitinib
• VVN461
• EYS606
• SFA 004
• TRS01
• RAY 121

This product will be delivered within 2 business days.